Globus Medical (GMED) Cash & Equivalents (2011 - 2026)

Globus Medical (GMED) has 16 years of Cash & Equivalents data on file, last reported at $560.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 21.61% year-over-year to $560.9 million; the trailing twelve-month figure through Mar 2026 stood at $560.9 million (up 21.61% YoY), and the FY2025 full-year result was $526.2 million, down 32.93% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $560.9 million, up from $526.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $784.4 million in Q4 2024 and bottomed at $134.2 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $354.1 million (2024), against an average of $368.1 million.
• The widest annual swing landed in 2022, when Cash & Equivalents sank 62.91%; it then jumped 210.56% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $150.5 million in 2022, then surged by 210.56% to $467.3 million in 2023, then jumped by 67.87% to $784.4 million in 2024, then tumbled by 32.93% to $526.2 million in 2025, then increased by 6.61% to $560.9 million in 2026.
• The last three Cash & Equivalents figures came in at $560.9 million (Q1 2026), $526.2 million (Q4 2025), and $371.8 million (Q3 2025), per Business Quant data.

Peer Comparison